Position in ABUS
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$11,992,234
-$8,882,882 QoQ
Shares Held
2,664,941
-38.6% QoQ
Ownership
1.35%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2024
9 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ABUS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026ADAGE CAPITAL PARTNERS GP, L.L.C. holds $4,240,035,723 across 126 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ROIV |
Roivant Sciences Ltd.
|
10,349,328 | $366,262,717 | |
| 2 | PRAX |
Praxis Precision Medicines, Inc.
|
1,015,480 | $339,972,549 | |
| 3 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
393,964 | $195,693,737 | |
| 4 | TNGX |
Tango Therapeutics, Inc.
|
5,600,000 | $175,056,000 | |
| 5 | BBIO |
BridgeBio Pharma, Inc.
|
2,252,000 | $167,728,960 | |
| 6 | SYRE |
Spyre Therapeutics, Inc.
|
1,722,300 | $152,905,794 | |
| 7 | TVTX |
Travere Therapeutics, Inc.
|
2,569,356 | $145,965,114 | |
| 8 | RPRX |
Royalty Pharma plc
|
2,500,000 | $140,175,000 |
All Filings in ABUS
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $11,992,234 | 2,664,941 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $20,875,116 | 4,339,941 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $22,767,832 | 5,014,941 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $7,959,657 | 2,575,941 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $5,500,034 | 1,575,941 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $5,398,577 | 1,650,941 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $11,168,622 | 2,900,941 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $9,270,000 | 3,000,000 | Shares | Sole | 2024-08-14 | |
| 2024-03-31 | $7,740,000 | 3,000,000 | Shares | Sole | 2024-05-15 | |
| No filing history on record for this holder in this stock. | ||||||